MetaCap

Arcutis Biotherapeutics Inc. (ARQT)

NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

26.36-0.81 (-2.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ARQT stock chart

Technical analysis

Key statistics

All statistics
P/E (TTM)
119.82
52-week range
19.30 – 34.80
Day range
26.29 – 27.46
Volume / Avg
1.29M / 2.58M
Beta
—

52-week range

$19.30$34.80

ARQT stock today

Arcutis Biotherapeutics (ARQT) closed at $26.36 on Nov 20, down 2.98% (-$0.81), versus the S&P 500's 3.70% decline. Trading was light, with 1.29M shares changing hands, about 50% of the average daily volume. At this level, ARQT sits in the middle of its 52-week range of $19.30 to $34.80: 24.3% below the high, set on Nov 4, 2026 and 36.6% above the low.

ARQT is down 9.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 10.6%. Arcutis Biotherapeutics trades at 119.8x its trailing twelve-month earnings per share of $0.22. Its forward P/E of 24.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Arcutis Biotherapeutics

Company profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Todd Franklin Watanabe M.A.
Headquarters
Westlake Village, CA
Employees
354
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Arcutis Biotherapeutics generated $376.1 million in revenue, up 91.3% from fiscal 2024, its 4th consecutive year of revenue growth. Arcutis Biotherapeutics reported a net loss of $16.1 million, compared with a loss of $140.0 million a year earlier. Gross margin was 90.2% (flat year over year) and operating margin -3.3%.

Arcutis Biotherapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$376.07M$196.54M$59.61M$3.69M$0
Growth+91.34%+229.74%+1517.09%——
Net income$-16.14M$-140.04M$-262.14M$-311.46M$-206.36M
EPS (diluted)$-0.13$-1.16$-3.78$-5.66$-4.18

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$40.38+53.19%

  • Strong buy 2
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $34.00High $48.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.06 vs $0.17
Surprise
-64.71%

ARQT news

All ARQT news

Arcutis Biotherapeutics peers

Health Care sector
ARQT peer companies
CompanyPrice% ChgMarket capCompare
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs ARQT
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs ARQT
IRONDisc Medicine Inc.75.14-1.27%$3.42Bvs ARQT
ELVNEnliven Therapeutics Inc.46.53+0.26%$3.42Bvs ARQT
PBLSParabilis Medicines Inc.27.44-0.67%$3.44Bvs ARQT
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs ARQT
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs ARQT
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs ARQT

Indexes, lists and sector

Arcutis Biotherapeutics stock FAQ

What is Arcutis Biotherapeutics's stock price today?

ARQT last traded at $26.36 as of Nov 20, 4:00 PM EST, down 2.98% on the day. Prices are delayed at least 15 minutes.

What is ARQT's P/E ratio?

ARQT trades at a trailing P/E ratio of 119.82 and a forward P/E of 24.09.

Who is Arcutis Biotherapeutics's CEO?

Mr. Todd Franklin Watanabe M.A. is the chief executive officer of Arcutis Biotherapeutics Inc., which has about 354 employees.

What is the ARQT 52-week high?

The 52-week high for ARQT is $34.80 and the 52-week low is $19.30. The stock is currently 24.3% below its high.

Compare ARQT